Other News To Note
Wednesday, January 4, 2012
TiGenix NV, of Leuven, Belgium, and its subsidiary Cellerix SA, of Tres Cantos, Spain, will receive about $3.8 million from the European Seventh Framework Programme to support the development of their Cx611 program of allogeneic expanded adipose-derived stem cells to treat rheumatoid arthritis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.